These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23656656)

  • 41. [Calcimimetic drugs in stage 3-5 chronic kidney disease].
    Grzegorzewska AE; Niepolski L
    Pol Merkur Lekarski; 2012 Apr; 32(190):260-2. PubMed ID: 22708286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cinacalcet may prolong the QT interval in patients on haemodialysis with secondary hyperparathyroidism.
    Borrego-Utiel FJ; Pérez-del Barrio Mdel P; Biechy-Baldan Mdel M; Segura-Torres P
    Nefrologia; 2013; 33(2):272-3. PubMed ID: 23511764
    [No Abstract]   [Full Text] [Related]  

  • 44. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
    Ogata H; Koiwa F; Ito H; Kinugasa E
    Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease.
    de Francisco AL; Piñera C; Palomar R
    Nat Clin Pract Nephrol; 2008 Jul; 4(7):366-7. PubMed ID: 18506170
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment with cinacalcet in secondary hyperparathyroidism for dialysis patients: The will is good--but what about the evidence?].
    Bárány P; Elinder CG; Samuelsson O
    Lakartidningen; 2013 Aug 21-Sep 3; 110(34-35):1481-3. PubMed ID: 24044187
    [No Abstract]   [Full Text] [Related]  

  • 47. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.
    Ureña Torres PA; Chanard J
    N Engl J Med; 2004 Jul; 351(2):188-9; author reply 188-9. PubMed ID: 15250062
    [No Abstract]   [Full Text] [Related]  

  • 49. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Moe SM; Abdalla S; Chertow GM; Parfrey PS; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Dehmel B; Goodman WG; Drüeke TB;
    J Am Soc Nephrol; 2015 Jun; 26(6):1466-75. PubMed ID: 25505257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal TARGETs for cardiovascular safety and benefit in ESRD.
    Sane DC
    Nephrol Dial Transplant; 2008 Oct; 23(10):3370-1; author reply 3371-2. PubMed ID: 18647742
    [No Abstract]   [Full Text] [Related]  

  • 51. [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
    Sułowicz W
    Przegl Lek; 2006; 63 Suppl 3():3-9. PubMed ID: 16898475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cinacalcet and Clinical Outcomes in Dialysis.
    Komaba H; Fukagawa M
    Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means.
    Drüeke TB
    Pediatr Nephrol; 2005 Mar; 20(3):399-403. PubMed ID: 15662538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice - the ECHO observational study: French experience].
    Ureña P; Fouque D; Brunet P; Touam M; Réglier JC
    Nephrol Ther; 2012 Dec; 8(7):527-33. PubMed ID: 23018042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cinacalcet hydrochloride: a viewpoint by Sharon M. Moe.
    Moe SM
    Drugs; 2005; 65(2):282-3. PubMed ID: 15631547
    [No Abstract]   [Full Text] [Related]  

  • 56. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
    Komaba H; Fukagawa M;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease.
    Coyne DW
    Nat Clin Pract Nephrol; 2008 Jul; 4(7):364-5. PubMed ID: 18477990
    [No Abstract]   [Full Text] [Related]  

  • 59. [Cinacalcet - an allosteric enhancer at the Ca2+-receptor].
    Kebig A; Mohr K
    Dtsch Med Wochenschr; 2008 Aug; 133(33):1681-3. PubMed ID: 18661462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. First treatment for serious complications of kidney disease, parathyroid cancer.
    FDA Consum; 2004; 38(3):6. PubMed ID: 15218832
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.